sorafenib has been researched along with Bronze Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aracil, C; Bruix, J; Bustamante, J; de la Mata, M; Del Val, A; Matilla, A; Pascasio, JM; Pascual, S; Reig, M; RodrÃguez, M; Turnes, J; Varela, M | 1 |
| Hoshida, Y; Newell, P; Villanueva, A | 1 |
1 review(s) available for sorafenib and Bronze Diabetes
| Article | Year |
|---|---|
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States | 2010 |
1 other study(ies) available for sorafenib and Bronze Diabetes
| Article | Year |
|---|---|
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Early Diagnosis; Embolization, Therapeutic; Female; Hemochromatosis; Hepatectomy; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mass Screening; Niacinamide; Obesity; Phenylurea Compounds; Prospective Studies; Pyridines; Registries; Retrospective Studies; Sorafenib; Spain; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |